IL17RA and asthma: Despite good results in preclinical studies, brodalumab, an anti–IL-17Rα MAb, had no effect on asthma control questionnaire score, FEV1, symptom scores, or number of symptom-free days in 302 subjects with inadequately controlled moderate-severe asthma taking regular ICSs.